Ramipril - Hypertension

Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00325806

Enrollment

1008

Registered

2006-05-15

Start date

2000-05-31

Completion date

2005-08-31

Last updated

2013-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Primary objective: Mean values of systolic and diastolic office blood pressure Secondary objectives: Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

Interventions

DRUGRamipril

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* no previous antihypertensive therapy * high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)

Exclusion criteria

* antihypertensive therapy * blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

Design outcomes

Primary

Measure	Time frame
Mean systolic and diastolic 24-hour blood pressure in ABPM	—

Secondary

Measure	Time frame
Overall mortality and total number of cardiovascular and cerebro-vascular events	—
Changes in mean blood pressure readings over time	—
Reasons for admissions to hospital/-stays	—
Occurrence of pathological fasting glucose levels in serum/pathological HbA1c levels.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026